Continuing the Patient-Centered Dialogue

09.26.14 | By

Subscribe buttonAs PhRMA’s Kaelan Hollon noted, “This year’s PhRMA national survey is a reminder to everyone in the biopharmaceutical industry of why it’s so i

Week in Review: Being Well-Informed About Health

09.19.14 | By

There has been a marked increase in media attention on the health care landscape over the past year. Some of these stories got it right, while others were often confusing or misleading.

New Morning Consult Column by PhRMA CEO Highlights Industry’s Role in Preventing Prescription Drug Abuse

09.18.14 | By

Subscribe buttonThis morning, our CEO John Castellani wrote a great Morning Consult column highlighting our policy platforms supporting the prevention of prescription drug abuse, in light of the recent release of new DEA

Survey Finds Minority Communities Have Distinct Health Concerns, Face Barriers to Reaching Ideal Health

09.16.14 | By

While the majority (66 percent) of Americans continue to be optimistic about their health, minority communities have unique and distinct health concerns and barriers to reaching their ideal health, according to PhRMA’s Second Annual National Health Survey.

The survey revealed that while 67 percent of whites and 67 percent of Hispanics reported they have had a good year when it comes to their health, African Americans ranked their health less favorably at 57 percent.

Driving Amazing R&D Progress

09.02.14 | By

We are on the cusp of amazing progress in U.S. biopharmaceutical research and development, but without policies that help attract and retain research-based companies and partnerships to help bring new medicines to patients, we run the risk of losing our country’s competitive advantage.

One Stop for Innovation: PhRMA’s New

08.26.14 | By

It’s likely many of us have paused to think about what life would have been like in a bygone time and felt thankful for the modern comforts we enjoy, from refrigeration to cell phones. When looking at the progress we’ve made and the comforts we enjoy, medical innovation should be at the top of the list. Over the past 100 years, life expectancy has surpassed 80 years, devastating diseases have been eradicated and quality of life has dramatically improved.

Modi’s New Era Has Begun

07.31.14 | By

Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S. and India since Modi’s election in May.

Weighing-in on the Cost and Value of Innovation

07.31.14 | By

Earlier this week, PhRMA participated in the Wall Street Journal’s first tweet chat hosted by Ed Silverman, who spearheads the publication’s blog, Pharmalot.

World Hepatitis Day: Driving Momentum to Help Patients

07.29.14 | By

For the millions of patients battling hepatitis C, World Hepatitis Day will hopefully be a day that is only read about in history books.

Now, more than ever before, there is great hope on the horizon as new and forthcoming medicines can provide nearly all patients fighting this disease with a cure. 

Assessing the Long-Term Value of Hepatitis C Treatments

07.25.14 | By

The current debate regarding the cost of new and forthcoming hepatitis C treatments has brought to light a long-standing discussion about the cost and value of innovative new medicines.


Subscribe to RSS - Opinion